CymaBay Therapeutics, Inc.
cymabay.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2023 10-K, filed Feb 28, 2024. Its latest SEC filing is a 15-12G from Apr 1, 2024.
10-K for FY2023, filed Feb 28, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops seladelpar, an investigational treatment for primary biliary cholangitis, for patients with liver disease.
10-K for FY2023, filed Feb 28, 2024
How Did They Make Money?
Drug-development collaborators pay for rights to develop, manufacture or commercialize candidates, and contracts may also include research funding, product supply, milestones and royalties on product sales. Payments follow each contract: license fees can be upfront, milestones depend on achievement, and royalties are tied to partner sales.
10-K for FY2023, filed Feb 28, 2024Collaboration RevenuesView ↗
The Company periodically enters into collaboration arrangements with third party collaborators, under which the Company may license certain…View ↗
The Company receives payments from its customers based on payment terms established in each contract. Upfront payments and fees are…View ↗
: Depending on facts and circumstances, the Company may conclude that it is appropriate to include a milestone payment in the estimated…View ↗
Sales-based Milestone and Royalty Payments:View ↗
$31.1M
-
10-K for FY2023, filed Feb 28, 2024
$31.1M ↗
Who Were Their Customers?
Works with third-party drug-development collaborators that license rights to develop, manufacture or commercialize its candidates; partners may also fund research and development or pay for product supply.
10-K for FY2023, filed Feb 28, 2024
Did Revenues Turn Into Profits?
No. It lost $105.4M in FY2023.
10-K for FY2023, filed Feb 28, 2024
−$101.7MView ↗
10-K for FY2023, filed Feb 28, 2024
−$105.4MView ↗
10-K for FY2023, filed Feb 28, 2024
−$72.9MView ↗
How Were They Changing?
-
Mar 22, 2024
Gilead completed its acquisition of CymaBay
The tender offer closed, and Purchaser merged into CymaBay, which remained the surviving corporation.
Sources
8-K, filed Mar 22, 2024
The Offer expired at one minute after 11:59 p.m. Eastern Time on March 21, 2024 (the “Expiration Time”) and was not extended. According to…View ↗
Narrower drug-development focus
The older report described a broader pipeline, including candidates for diabetes and inflammation and seladelpar for PBC and NASH; the latest report focuses primarily on seladelpar, with PBC as its initial launch target.
10-K for FY2020, filed Mar 25, 2021), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and…View ↗
CymaBay Pipeline OverviewView ↗
Product Candidates Disease/condition Status Description Seladelpar (PPARd agonist) Primary Biliary Cholangitis (PBC) Phase 3 Ongoing…View ↗
Who Did They Compete With?
Competes with Intercept Pharmaceuticals, Alfasigma, Genfit, Ipsen, Zydus Lifesciences, Calliditas Therapeutics, and GSK
10-K for FY2023, filed Feb 28, 2024Currently, the only FDA-approved treatments for PBC are ursodeoxycholic acid (UDCA), also known as ursodiol, an isomer of chenodeoxycholic…View ↗
Loading...
